**Abstract**

**Background:** Human parvovirus B19 is the etiologic agent of erythema infectiosum in children. It is also associated with other clinical manifestations in different target groups. Patients with chronic hemolytic anemia are at high risk of developing acute erythroblastopenia following infection by the virus. They usually become highly viremic and pose an increased risk of virus transmission. Close monitoring of such high risk groups is required for epidemiologic surveillance and disease prevention activities. Here we report a molecular epidemiological study on B19 virus infection in Tunisian patients with chronic hemolytic anemia.

**Methods:** This study was conducted on 92 young chronic hemolytic anemia patients who attended the same ward at the National Bone Marrow Transplantation Center of Tunis and 46 controls from a different hospital. Screening for IgM and IgG anti-B19 antibodies was performed using commercially available enzyme immunoassays and B19 DNA was detected by nested PCR in the overlapping VP1/VP2 region. DNA was sequenced using dideoxy-terminator cycle sequencing technology.

**Results:** Anti-parvovirus B19 IgG antibodies were detected in 26 of 46 sickle-cell anemia patients, 18 of 46 β-thalassemia and 7 of 46 controls. Anti-parvovirus B19 IgM antibodies were detected only in 4 of the sickle-cell anemia patients: two siblings and two unrelated who presented with acute erythroblastopenia at the time of blood collection for this study and had no history of past transfusion. B19 DNA was detected only in sera of these four patients and the corresponding 288 bp nested DNA amplicons were sequenced. The sequences obtained were all identical and phylogenetic analysis showed that they belonged to a new B19 virus strain of Genotype 1.

**Conclusion:** A new parvovirus B19 strain of genotype 1 was detected in four Tunisian patients with sickle-cell anemia. Virus transmission appeared to be nosocomial and resulted in acute erythroblastopenia in the four patients. The possibility of independent transmission of this B19 variant to the patients is unlikely in light of the present epidemiological data. However this possibility cannot be ruled out because of the low genetic variability of the virus.
Background

Human parvovirus B19 belongs to the Erythrovirus genus of the Parvoviridae family and is the etiologic agent of erythema infectiosum or fifth disease in children [1,2]. Infections with this virus are very common and can result in a wide range of clinical manifestations depending on the patient’s immunological and hematological status. In immunocompetent individuals B19 infections can be asymptomatic or benign and may cause erythema infectiosum and arthopathy [3]. Immunodeficient subjects may become chronically infected [4,5]. During pregnancy, the virus can be transmitted in utero sometimes leading to fetal hydrops and fetal death [6,7].

Parvovirus B19 has a specific tropism for erythroïd progenitor cells and thus can cause a temporary infection of the bone marrow eventually leading to a transient arrest in erythropoiesis [8]. Patients with hematological disorders are at risk of severe clinical illness especially in chronic hemolytic anemia such as sickle cell disease [9,10], thalassemia [11] and hereditary spherocytosis [12]. In these diseases erythroid progenitor cell formation is increased to compensate for red blood cell lysis and B19 infection can suppress erythropoiesis and induce acute erythroblastopenia often referred to as transient aplastic crisis [13]. The patients usually become highly viremic and pose an increased risk of virus transmission. Close monitoring of such high risk groups for this viral infection is, therefore, of great importance for epidemiologic surveillance and disease prevention.

Parvovirus B19 is a highly conserved virus; however, molecular epidemiological studies have shown the existence of three distinct genotypes modestly diverging from each other in sequence by about 10% while not showing any apparent differences in pathogenicity [14]. Genotype 1 is represented by the prototype B19 virus and is the most prevalent. The first B19 variant to be discovered was V9 [15] which represents the rare genotype 3. Genotype 2 is substantially more frequent with representatives such as A6 and LaLi [16,17].

Here we report, for the first time, a molecular epidemiological study on Parvovirus B19 infection in Tunisian chronic hemolytic anemia patients.

Methods

Patients and sera

Sera used in this study were taken from 92 Tunisian patients with chronic hematological disorders: 46 sickle-cell anemia and 46 β-thalassemia. Forty six patients affected with non-hematological diseases (11 diabetes, 11 tonsillitis, 12 rhinitis, and 12 nephritic syndrome) were taken as controls. Patients of these groups were 2 to 19 years old with mean ages of 7.4 years for β-thalassemia, 9.2 years for sickle-cell anemia and 7.5 years for the control group. The chronic hemolytic anemia patients attended the same ward at the National Bone Marrow Transplantation Center of Tunis for treatment and follow up, and the control group was from the Charles Nicolles Hospital, Tunis. Written informed consent was obtained from all individuals included in this study or their parents. All the work was conducted in compliance with the Helsinki Declaration and approved by the National Ethics Committee of Tunisia.

Detection of anti-Parvovirus B19 antibodies

Specific enzyme immunoassays (Biotrin International, France) were used to detect anti-Parvovirus IgG and IgM in sera according to the instructions of the manufacturer. The colorimetric reaction was read using the LP 200 microplate reader (Diagnostic Pasteur, France). Statistical significance of the serologic data was assessed by the Chi-square test for equality of distributions.

Detection of viral DNA

All necessary precautions were taken to prevent cross contamination. DNA extraction, PCR reagent preparation, DNA amplification and gel electrophoresis were carried out in separate rooms using separate sets of micropipettes and sterile filter-tips. In addition, DNA extraction and PCR reagent handling were done in dedicated safety cabinets under sterile conditions.

Undiluted sera (200 µl) were digested with 2 µl of protease k (20 mg/ml) at 56°C for 1 h. Insoluble aggregates were removed by centrifugation at 13000 × g for 30 min. DNA was extracted using the QiAamp DNA Blood kit (Qiagen, Hilden, Germany) as described by the manufacturer.

Nested PCR for the detection of B19 DNA was performed using two primer pairs [20] selected in the overlapping region common to the minor (VP1) and major (VP2) capsid protein genes. The outer primers were: sense, 5'-CAAAAGCATGTGGAGTGAGG-3' (nt 3187–3206); antisense, 5'-CTACTAACATGCATAGGCGC-3' (nt 3584–
Target DNA was amplified in a 50 μl reaction mixture containing 5 μl of sample DNA, 50 mM KCl, 10 mM Tris-HCl (pH = 8.3), 1.5 mM MgCl2, 200 μM of each deoxyribonucleoside triphosphate, 1.25 U of Taq DNA polymerase (Promega) and either 0.5 μM of each outer primer or 1.0 μM of each inner primer.

Each PCR run included a blank control containing water instead of target DNA, a negative control consisting of DNA extracted from healthy human leucocytes appropriately diluted in normal human serum, and a positive control; the latter was prepared from a first-round PCR product obtained previously (Regaya et al, 2003). Additional precautions were taken in handling this PCR product. First, it was maximally diluted in normal human serum to minimize the possibility of cross contamination while still allowing reproducible amplification. Second, this B19 amplicon was sequenced prior to use for future reference in case of suspected cross contamination.

Amplification reactions were performed with a thermocycler program consisting of 30 cycles of denaturation at 94°C for 1 minute, annealing for 2 minutes at either 55°C with the outer primers, or 57°C with the inner primers, and extension at 72°C for 3 minutes. A final 5-minute extension step was added after the last cycle. Two microliters of the product obtained in the first PCR were subjected to the second PCR using the inner primers.

For the detection of amplified DNA, five microliters of each product from the first or second PCR round were subjected to electrophoresis in 2% agarose gels in the presence of ethidium bromide and visualized under UV light. DNA bands were consistently absent from agarose gel for B19 DNA, i.e. 398 bp in the first round (Figure 1A) and 288 bp in the second round (Figure 1B) of PCR. Such amplicons with electrophoretic bands of the size expected for B19 DNA were positive for anti-B19 IgM antibodies; and 2 were also positive for anti-B19 IgG (Table 2). All four patients were diagnosed with acute erythroblastopenia at the time of blood collection for this study and had no past transfusion history. They presented with fever, malaise, pallor and no cutaneous rash. Laboratory evaluation showed severe anemia and profound reticulocytopenia (Table 2). The four patients recovered progressively following red cell transfusion. All the IgG positive/IgM negative patients presented with no symptoms of acute erythroblastopenia.

**PCR results**

Nested PCR in the overlapping VP1/VP2 region of the B19 genome was carried out on all anti-B19 antibody positive sera. Only sera from the four anti-B19 IgM-positive patients with acute erythroblastopenia produced DNA amplicons with electrophoretic bands of the size expected for B19 DNA, i.e. 398 bp in the first round (Figure 1A) and 288 bp in the second round (Figure 1B) of PCR. Such DNA bands were consistently absent from agarose gel lanes corresponding to the negative and blank controls.

**Table 1: Serological data of the patients with chronic hematological disorders and control group**

| Group tested | Number | IgM | % | Number | IgG | % |
|--------------|--------|-----|---|--------|-----|---|
| Sickle-cell anemia | 46 | 4 | 8.7 | 26 | 56.5 |
| β-thalassemia | 46 | 0 | 0 | 18 | 39.1 |
| Control | 46 | 0 | 0 | 7 | 15.2 |
throughout all our PCR work. These results showed the presence of parvovirus B19 DNA in only the sera of the four acutely infected IgM positive patients and indicated the absence of detectable chronic infection in the IgG positive/IgM negative subjects. The B19 virus isolates corresponding to the amplified DNA from the four acute erythroblastopenia patients were designated R1 to R4.

**Phylogenetic analysis**

In order to identify the possible route of virus transmission to the four sickle-cell anemia patients and to know the genotype and sequence diversity of virus isolates R1, R2, R3, and R4, we purified and sequenced their nested DNA amplicons. Partial 237 nucleotide sequences were obtained from the sequencing data and aligned in BioEdit with ClustalW (not shown). The four sequences appeared to be identical, thus indicating that isolates R1 to R4 belonged to a single virus strain. The corresponding nucleotide sequence (R) was aligned in BioEdit with ClustalW against selected representatives of the three known B19 virus genotypes retrieved from GenBank (Figure 2) and a phylogenetic tree was constructed using DNAMLK and TreeView (Figure 3). Sequence R clustered with reference strains of genotype 1. This sequence also produced many significant alignments in nucleotide BLAST (NCBI) and showed a maximum of 235/237 (99%) nucleotide identities with 11 reference strains of genotype 1 (not shown). A characteristic (T ↔ C) transition at position 40 was found exclusively in our isolates and in Kati 4 [GenBank: AF161226.1]. This transition is represented in the alignment of Figure 2. All these substitutions were silent as shown by alignment of sequence R in BLASTX (NCBI; not shown). Taken together, these data indicated that the virus isolates detected here represent a new B19 virus strain of genotype 1.

**Discussion**

Acute erythroblastopenia is the first disease to be associated with parvovirus B19 [9]. In predisposed patients such as those affected with chronic hemolytic anemia, 70 to 80% of erythroblastopenia cases are caused by infection with this virus. The infected patients usually become highly viremic and pose an increased risk of B19 virus transmission [11,13]. Close monitoring of such high risk groups is required to acquire data on parvovirus infection for the formulation of epidemiological surveillance programs and prevention strategies.

In this work we studied a population of 92 young Tunisian patients with chronic hemolytic anemia who attended the same ward at the National Bone Marrow Transplantation Center of Tunis. The control group consisted of patients with non-hematological disorders from different wards at a nearby hospital. The serological data obtained showed a much higher rate of past B19 infection in the chronic hemolytic anemia patients, as indicated by specific IgG. This situation may have resulted from a combination of known risk factors for B19 infection such as the presence of highly viremic patients, nosocomial transmission [23], and transfusion-related transmission [24].

Comparison between the present serological data and those previously reported in Tunisian blood donors [18] and patients with chronic rheumatoidal disorders [19] illustrates the effect of age in the determinism of prevalence in B19 virus infection. The much older groups in the previous studies belonged to lower risk categories for B19 infection, yet they showed a significantly higher prevalence of past infection by the virus than the present high risk population. This observation corroborates published

---

**Table 2: Laboratory findings for the four parvovirus B19-infected sickle-cell anemia patients**

| Patient | Anti-B19 IgM | Hemoglobin pattern | Hemoglobin Concentration (g/dl) | Erythrocyte count (10⁶ cells/µl) | Reticulocyte count (cells/µl) |
|---------|--------------|--------------------|---------------------------------|---------------------------------|-------------------------------|
| 1       | +            | S/β₀               | 5.5                             | 1.90                            | 3880                          |
| 2       | +            | S/β₀               | 4.7                             | 1.66                            | 8300                          |
| 3       | -            | S/S                | 4.3                             | 1.57                            | 7850                          |
| 4       | -            | S/S                | 5.0                             | 2.34                            | 11700                         |

**Figure 1**

Agarose gel electrophoresis pattern of parvovirus B19 DNA amplicons. (A) 398 bp DNA bands obtained in the first round of PCR; (B) 288 bp DNA bands obtained in the second round of PCR. M: molecular weight marker (100 bp ladder, Invitrogen). P: positive control; lanes 1 to 4: amplicons of sera from patients 1 to 4, respectively.
Alignment of the partial DNA sequence of the four B19 isolates with reference strains

Figure 2
Alignment of the partial DNA sequence of the four B19 isolates with reference strains. The partial VP1/VP2 DNA sequence (R) representing the four B19 virus isolates R1 to R4 was aligned with representative sequences of the three human parvovirus genotypes retrieved from GenBank. Accession numbers were as follows. Genotype 1: OsFr [GenBank: DQ225150.1]; Kati 4 [GenBank: AF161226.1]; AnTo [GenBank: DQ225151.1]; SN807 [GenBank: DQ225149.1]; NAN [GenBank: AY304945.1]; J35 [GenBank: AY386330.1]; B19-Au [GenBank: M13178.1]. Genotype 2: LaLi [GenBank: AY345134.1]; D91.1 [GenBank: AY386324.1]; BN30.3 [GenBank: AY345134.1]. Genotype 3: V9 [GenBank: AY345134.1]; BN30.3 [GenBank: AY345134.1]; R0748 [GenBank: DQ234779.1].
epidemiological reports indicating that this infection spreads at a high rate in low age groups to reach 50% of young adolescents by age 15, and continues at a lower rate throughout adult life to reach most of the elderly [25,26].

Four of the chronic hemolytic anemia patients were found to be acutely infected by the parvovirus as shown by the presence of specific IgM and viral DNA in their serum. The corresponding virus isolates had identical partial VP1/VP2 DNA sequences and therefore appeared to represent a single B19 strain, thus pointing towards nosocomial transmission. Since nosocomial transmission of B19 infection is documented [23,27] and since the patients had no past transfusions, the presence of the same virus strain in the four patients can be interpreted as the result of nosocomial transmission. An alternative explanation would be that the detected B19 strain is a hitherto unknown variant circulating independently of hospital settings. This possibility is also in conformity with the present genetic and phylogenetic analysis. Indeed, when the DNA sequence (R) representing this strain was aligned in nucleotide BLAST, it showed a maximum of 235/237 (99%) nucleotide identities with the closest reference strains, and a characteristic (T ↔ C) transition at nucleotide position 40 of R. This transition was also found in the Kati-4 strain which otherwise showed only 232/237 (97%) nucleotide identities with R. These findings indicated that the virus isolates represented a new B19 virus strain and phylogenetic analysis showed that it belongs to genotype1. Thus, the possibility that this strain is a newly identified circulating variant cannot be disregarded in view of the low variability of the VP1/VP2 gene [14,28]. However, it does not exclude the possibility of nosocomial transmission which is strongly suggested by the epidemiological data. Sequencing of a larger part of the genome of the present isolates, especially in the more variable VP1 unique region [27] and further detection and analysis of other isolates from Tunisia would be needed to confirm virus transmission and strain identity.

It is noteworthy, that all the nucleotide differences observed between this new strain and the reference strains of genotype1 in nucleotide BLAST were synonymous as shown by alignment of sequence R in BLASTX. This further confirmed the lower variability of the VP1/VP2 region at the protein level than at the DNA level [27].

**Conclusion**

Four patients with sickle-cell anemia who presented with acute erythroblastopenia were found to be acutely infected by the B19 parvovirus. Analysis of the Partial viral DNA sequence in the overlapping VP1/VP2 region indicated the four patients were infected by a single B19 variant strain of genotype1. Virus transmission to the four patients was most probably nosocomial according to the epidemiological data. The molecular data were in line with this mode of transmission but could not fully confirm it because of the known low variability of the B19 genome especially in the VP1/VP2 gene. Final confirmation of transmission will await sequencing of longer and more variable regions of the viral genome.

**Competing interests**

The author(s) declare that they have no competing interests.

**Authors’ contributions**

FR conceived the epidemiological studies, carried out the immunoassays and the PCR, participated in sequence alignments and drafted the manuscript. LO carried out DNA sequencing and participated in sequence analysis. MB established the diagnosis, collected the sera and compiled the clinical data. MK and MZ participated in the design of the study and its coordination. RK supervised the study, participated in its design, and finalized the manuscript. All authors read and approved the final manuscript.
Acknowledgements
We thank Professor Abdellatif Boudabbous of the Faculty of Sciences of Tunis, for valuable help and advice, and the Ministry of Higher Education and Scientific Research and Technology, for funding.

References
1. Young NS, Brown KE. Parvovirus B19. N Engl J Med 2004, 350:586-597.
2. Anderson MJ, Jones SE, Fisher-Hoch SP, Lewis E, Hall SM, Bartlett CLR, Cohen BJ, Mortimer PP, Pereira MS: Human parvovirus, the cause of erythema infectiosum (fifth disease)? Lancet 1983, i:1378.
3. Plummer FA, Hammond GW, Forward K, Selda L, Thompson LM, Jones SE, Kidd IM, Anderson MJ: An erythema infectiosum-like illness caused by human Parvovirus infection. N Engl J Med 1983, 315:74-79.
4. Kurtzman GJ, Ozawa K, Cohen B, Hanson G, Oseas R, Young NS: Chronic bone marrow failure due to persistent B19 parvovirus infection. N Engl J Med 1987, 317:287-294.
5. Kurtzman GJ, Cohen B, Meyers P, Annallah A, Young NS: Persistent B19 parvovirus infection as a cause of severe chronic anemia in children with acute lymphocytic leukemia. Lancet 1988, ii:1159-1162.
6. Brown T, Anand A, Ritchie LD, Clewley JP, Reid TMS: Intrauterine parvovirus infection associated with hydrops fetalis. Lancet 1984, ii:1033-1034.
7. Levy R, Weissman A, Blomberg G, Hagay ZJ: Infection byparovirus B 19 during pregnancy: a review. Obstet Gynecol Surv 1997, 52:254-259.
8. Ozawa K, Kurtzman G, Young N: Replication of the B19 parvo-
irus in human bone marrow cell cultures. Science 1986, 233:883-886.
9. Pattison JR, Jones SE, Hodgson J, Davis LR, White JM, Stroud CE, Mur-
taza L: Parvovirus infections and hypoplastic crisis in sickle-cell anemia. Lancet 1981, ii:664-665.
10. Serjeant GR, Serjeant BE, Thomas PW, Anderson MJ, Patou G, Patt-
sion JR: Human Parvovirus B19 infection in homozygous sickle cell disease. Lancet 1993, 341:1237-1240.
11. Guerine J, Courouce AM, Bertrand Y, Girot R, Soulier JP: Human parvovirus and aplastic crisis in chronic hemolytic anemias: a study of 24 observations. Am J Hematol 1986, 23:271-275.
12. Davidson RJ, Brown T, Wiseman D: Human parvovirus infection and aplastic crisis in hereditary spherocytosis. J Infect 1984, 9:298-300.
13. Chorba T, Coccia P, Holman RC, Tattersall P, Anderson LJ, Sudman J, Young NS, Kurczynski E, Saarinen UM, Moir R: The role of parvovirus B19 in aplastic crisis and erythema infectiosum (fifth disease). J Infect Dis 1986, 154:383-393.
14. Servant A, Laperche S, Lallemant F, Marinho V, De Saint-Maur G, Meritet JF, Garbarg-Chenon A: Genetic diversity within human erythroviruses: identification of three genotypes. J Virol 2002, 76:9124-9134.
15. Nguyen QT, Sifer C, Schneider V, Allauze X, Servant A, Bernaudin F, Auguste V, Garbarg-Chenon A: Novel human erythrovirus associated with transient aplastic anemia. J Clin Microbiol 1999, 37:2483-2487.
16. Nguyen QT, Wong S, Heegaard ED, Brown KE: Identification and characterization of a second novel erythrovirus variant, A6. Virology 2002, 301:374-380.
17. Hoknary K, Soderlund-Venermo M, Pesonen M, Ranik A, Kiviluoto O, Partio EK, Hedman K: A new parvovirus genotype persistent inhuman skin. Virology 2002, 302:224-228.
18. Letasif M, Vanham G, Boukef Y, Muytle L, Mertens G: Higher prevalence of parvovirus B19 in Belgian as compared to Tunisian blood donors: differential implications for prevention of transfusional transmission. Transfus Sci 1997, 18:523-530.
19. Beegun F, Khelfa R, Zouari R, Kchir M, Karoui M, Essid R: Research on Parvovirus B19 infections and chronic articular manifestations in a Tunisian hospital. Arch Inst Pasteur Tunis 2003, 80:9-15.
20. Yamakawa Y, Oka H, Horii S, Araki T, Izumi R: Detection of human parvovirus B19 DNA by nested polymerase chain reaction. Obstetrics & Gynecology 1995, 86:126-159.
21. Hall TA: BioEdit: biological sequence alignment editor for Windows 95/98/NT version 5.0.7. [http://www.mbio.ncsu.edu/BioEdit/bioedit.html].
22. Page RDM: TreeView: an application to display phylogenetic trees on personal computers. Computer Applications in the Biosciences 1996, 12:357-358.
23. Bell LM, Naides SJ, Stoffman P, Hodinka RL, Plotkin SA: Human parvovirus B19 infection among hospital staff members after contact with infected patients. N Engl J Med 1989, 321:485-491.
24. Azzi A, Morfini M, Mannucci PM: The transfusion-associated transmission of parvovirus B19. Transfus Med Rev 1999, 13:194-204.
25. Risks associated with human parvovirus B19 infection. MMWR Morb Mortal Wkly Rep 1989, 38:81-8. 93.
26. Human parvovirus B19 infections in United Kingdom 1984-86. Lancet 1987, i:738-739.
27. Takahashi N, Takada N, Hashimoto T, Okamoto T: Genetic hetero-
geneity of the immunogenic viral capsid protein region of human parvovirus B19 isolates obtained from an outbreak in a pediatric ward. FEBS Letters 1999, 450:289-293.
28. Erdman DD, Durigon EL, Wang QY, Anderson LJ: Genetic diver-
sity of human parvovirus B19: sequence analysis of the VP1/ VP2 gene from multiple isolates. J Gen Virol 1996, 77:2767-2774.

Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2334/7/123/prepub